Catalent pumping $200m into biomanufacturing expansions

Dan Stanton, Managing editor

November 7, 2018

2 Min Read
Catalent pumping $200m into biomanufacturing expansions
Catalent's Bloomington, Indiana facility is set to double its capacity. Image: iStock/LorenzoT81

Catalent plans to double fill/finish capacity at its Bloomington site and add a fourth and fifth train at its Madison drug substance facility.

During its fourth quarter FY2018 call, contract development and manufacturing organization (CDMO) Catalent said it was eyeing up a fourth and fifth biomanufacturing train at its Madison, Wisconsin plant.

And during its Q1 FY2019 investor call, CEO John Chiminski confirmed the board has approved both the expansion in Madison and a doubling of capacity at its Bloomington, Indiana plant, picked up through Catalent’s acquisition of Cook Pharmica in September 2017.


Catalent’s Bloomington, Indiana facility is set to double its capacity. Image: iStock/LorenzoT81

“Both of these are significant CapEx,” he told stakeholders. “In Madison, it’s just under $100 million [€87 million]. The one in Bloomington is just over $100 million that will be spent over the next three years.”

The build outs represent between 7% to 8% capital expenditure spend as a percent of revenue.

20 commercial products

For the first quarter FY2019, Catalent’s net revenue stood at $551 million, up 3% year-on-year. Revenue from the Biologics and Specialty Drug Delivery segment represented $155 million, up 69% on the same period last year, attributed mostly to the Cook acquisition.

Chiminski added the investments show “the confidence that our board has, and the demand that we’re seeing both on the drug substance side for Madison as well as the drug product for Bloomington.”

He illustrated this with the number of commercialized biologics drug products being processed at Bloomington.

“When we acquired Bloomington, we had 12 products that were commercialized with visibility to a dozen or so more that we thought would be commercialized over the next, I would say, 24 months. And as we sit here today, we already have 20 products that are commercialized.”

However, capacity utilization still sits at around 50-60% at the plant. “The challenge for us now is effectively allocating that capacity to the actual demand that is there. So we’re currently working through making sure that we’re doing more than allocating capacity we have and trying to fulfill the very strong robust demand that we have.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like